Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2006

01-07-2006 | Phase II Studies

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

Authors: Jaffer A. Ajani, Yixing Jiang, Josephine Faust, Baochong B. Chang, Linus Ho, James C. Yao, Steven Rousey, Shaker Dakhil, Richard C. Cherny, Catherine Craig, Archie Bleyer

Published in: Investigational New Drugs | Issue 4/2006

Login to get access
Metadata
Title
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
Authors
Jaffer A. Ajani
Yixing Jiang
Josephine Faust
Baochong B. Chang
Linus Ho
James C. Yao
Steven Rousey
Shaker Dakhil
Richard C. Cherny
Catherine Craig
Archie Bleyer
Publication date
01-07-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-6452-1

Other articles of this Issue 4/2006

Investigational New Drugs 4/2006 Go to the issue

Phase I Studies

A phase I study of flavopiridol and docetaxel

Preclinical Studies

The Wnt-dependent signaling pathways as target in oncology drug discovery

Preclinical Studies

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

Phase II Studies

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

Phase I Studies

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

Phase II Studies

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits